Javascript must be enabled to continue!
Impact of Donation After Circulatory Death on Waitlist Duration and Early Outcomes in Heart Transplantation for Patients With Durable Mechanical Circulatory Support
View through CrossRef
Abstract
Objective
While heart transplantation primarily relies on donors after brain death, the use of donors after circulatory death is increasing to address donor shortages. Although favourable outcomes with donation after circulatory death (DCD) have been reported, its safety in patients bridged with durable mechanical circulatory support (MCS) remains uncertain.
Design
Using the United Network for Organ Sharing database, we identified adult recipients supported with durable MCS who underwent isolated primary heart transplantation between 2019 and 2023. Outcomes were compared between recipients of hearts from donors after brain death and donors after circulatory death.
Results
Among 14 881 heart transplants, 3681 patients were supported with durable MCS, comprising 3374 (91.7%) recipients from donors after brain death and 307 (8.3%) from donors after circulatory death. Compared with recipients of hearts from donors after brain death, those receiving hearts from donors after circulatory death were more often male, had higher body mass index, lower ABO blood group compatibility, fewer pretransplant infections, less extracorporeal membrane oxygenation use, longer ischaemic times (3.5 vs 5.5 hours, P < .05), and shorter waitlist times (404.4 vs 336.9, P < .05). Survival was similar between groups (90.9% vs 93.2% at 6 months, 89.0% vs 90.2% at 1 year; P = .946). Cause of death and other adverse events were also comparable.
Conclusions
Utilizing DCD donors significantly reduces waitlist duration for patients with durable MCS. Although early post-transplant survival was statistically stable, definitive conclusions regarding survival equivalence involve several limitations. Further larger comparative studies with comprehensive donor characteristics are strictly required to evaluate the safety profile of DCD hearts in this high-risk recipient population.
Oxford University Press (OUP)
Title: Impact of Donation After Circulatory Death on Waitlist Duration and Early Outcomes in Heart Transplantation for Patients With Durable Mechanical Circulatory Support
Description:
Abstract
Objective
While heart transplantation primarily relies on donors after brain death, the use of donors after circulatory death is increasing to address donor shortages.
Although favourable outcomes with donation after circulatory death (DCD) have been reported, its safety in patients bridged with durable mechanical circulatory support (MCS) remains uncertain.
Design
Using the United Network for Organ Sharing database, we identified adult recipients supported with durable MCS who underwent isolated primary heart transplantation between 2019 and 2023.
Outcomes were compared between recipients of hearts from donors after brain death and donors after circulatory death.
Results
Among 14 881 heart transplants, 3681 patients were supported with durable MCS, comprising 3374 (91.
7%) recipients from donors after brain death and 307 (8.
3%) from donors after circulatory death.
Compared with recipients of hearts from donors after brain death, those receiving hearts from donors after circulatory death were more often male, had higher body mass index, lower ABO blood group compatibility, fewer pretransplant infections, less extracorporeal membrane oxygenation use, longer ischaemic times (3.
5 vs 5.
5 hours, P < .
05), and shorter waitlist times (404.
4 vs 336.
9, P < .
05).
Survival was similar between groups (90.
9% vs 93.
2% at 6 months, 89.
0% vs 90.
2% at 1 year; P = .
946).
Cause of death and other adverse events were also comparable.
Conclusions
Utilizing DCD donors significantly reduces waitlist duration for patients with durable MCS.
Although early post-transplant survival was statistically stable, definitive conclusions regarding survival equivalence involve several limitations.
Further larger comparative studies with comprehensive donor characteristics are strictly required to evaluate the safety profile of DCD hearts in this high-risk recipient population.
Related Results
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Patient-reported dyspnea and health predict waitlist mortality in patients waiting for lung transplantation in Japan
Patient-reported dyspnea and health predict waitlist mortality in patients waiting for lung transplantation in Japan
Abstract
Background
Waitlist mortality due to donor shortage for lung transplantation is a serious problem worldwide. Currently, the selection of recipients is mainly base...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Psychological well-being of identity-release egg donation parents with infants
Psychological well-being of identity-release egg donation parents with infants
Abstract
STUDY QUESTION
What are the psychological health, relationship quality and perceived social support outcomes of heteros...
Patient-reported dyspnea and health predict waitlist mortality in patients waiting for lung transplantation in Japan
Patient-reported dyspnea and health predict waitlist mortality in patients waiting for lung transplantation in Japan
Abstract
Background
Waitlist mortality due to donor shortage for lung transplantation is a serious problem worldwide. Cur...

